Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bamidele Olupona

Podiatrist, Foot & Ankle Surgery Miami, FL Doctor of Podiatric Medicine

NPI 1548502867 CMS profile 2297192

2601 Sw 37Th Ave Ste 604, Miami, FL 33133

Open in the dashboard

General payments

$12,238

148 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$55,275 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Bamidele Olupona of Miami, FL is reported in the CMS Open Payments database as having received $12,238 across 148 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $55,275 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $368 11
2024 General $540 11
2023 General $362 17
2022 General $3,353 26
2021 General $524 24
2020 General $882 25
2019 General $6,209 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bamidele Olupona
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Bamidele Olupona were reported at $368. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Bamidele Olupona Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $6,209 $389 $118–$1,406 $163
2020 $882 $191 $62–$691 $114
2021 $524 $329 $104–$1,341 $132
2022 $3,353 $419 $125–$1,611 $149
2023 $362 $377 $128–$1,164 $160
2024 $540 $394 $134–$1,168 $164
2025 $368 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Southern Edge Orthopaedics, Inc. $8,132 9 payments
  2. Stryker Corporation $597 16 payments
  3. Horizon Therapeutics plc $434 24 payments
  4. Smith+Nephew, Inc. $382 17 payments
  5. Nevro Corp. $279 8 payments
  6. Organogenesis Inc. $227 5 payments
  7. Wright Medical Technology, Inc. $214 4 payments
  8. Novo Nordisk Inc $162 9 payments
  9. Treace Medical Concepts, Inc. $136 2 payments
  10. ETS Wound Care LLC $132 1 payment
  11. Other $1,543 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $8,132 9 payments
  2. Food and Beverage $4,106 139 payments
Products named General payments · program years 2019–2025
  1. Omnia $261 7 payments
  2. SONICANCHOR $250 4 payments
  3. KRYSTEXXA $214 6 payments
  4. Puraply $205 4 payments
  5. Ozempic $162 9 payments
  6. RYBELSUS $162 9 payments
  7. MICA $141 2 payments
  8. LAPIPLASTY SYSTEM $136 2 payments
  9. COLLAGENASE SANTYL $133 4 payments
  10. MIRRAGEN ADVANCED WOUND MATRIX $132 1 payment
  11. Other $3,411 133 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

245

Median for Podiatry: 160

Drug cost

$4,451

Median for Podiatry: $2,368

Branded share of claims

6.5%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ammonium Lactate Generic 62 $1,735
Terbinafine Hcl Generic 69 $776
Celecoxib Generic 27 $687
Cephalexin Generic 11 $483
Methylprednisolone Generic 34 $227
Ketoconazole Generic 13 $224
Gabapentin Generic 13 $189
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 16 $130

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$66,938

Medicare's payments for the services billed

Medicare patients

725

Average age 78

Services billed

1,136

418 women, 307 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Alzheimer's or dementia 60%
Diabetes 58%
Chronic kidney disease 45%
Heart failure 44%
Ischemic heart disease 44%
Arthritis 42%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $11
$11 — —
QULIPTA
  • AbbVie, Inc. $11
$11 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

148 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record